Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Predicting late breast cancer recurrence with screening assays

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.17
Views: 842

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, UK

Prof Jack Cuzick speaks with ecancer at SABCS 2017 about predicting late breast cancer recurrence with screening assays.

He describes how gene panels, such as the one discussed by Dr Jonathan Lancaster here, came to be following ATAC and TransATAC trials, and have incorporated a wider array of gene signatures which may indicate likelihood of relapse.

Prof Cuzick goes on to consider the future of screening in cancer prevention strategies patient survival.

For more on prediction of distant disease recurrence, watch our interview with Dr Ivana Sestak here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation